Sinopharm Tech Holdings (HKSE:08156) Cash-to-Debt : 0.85 (As of Dec. 2023)

View and export this data going back to 2002. Start your Free Trial

What is Sinopharm Tech Holdings Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Sinopharm Tech Holdings's cash to debt ratio for the quarter that ended in Dec. 2023 was 0.85.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Sinopharm Tech Holdings couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Sinopharm Tech Holdings's Cash-to-Debt or its related term are showing as below:

HKSE:08156' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02 Med: 0.13 Max: No Debt
Current: 0.85

During the past 13 years, Sinopharm Tech Holdings's highest Cash to Debt Ratio was No Debt. The lowest was 0.02. And the median was 0.13.

HKSE:08156's Cash-to-Debt is ranked worse than
67.5% of 2723 companies
in the Software industry
Industry Median: 2.49 vs HKSE:08156: 0.85

Sinopharm Tech Holdings Cash-to-Debt Historical Data

The historical data trend for Sinopharm Tech Holdings's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Sinopharm Tech Holdings Cash-to-Debt Chart

Sinopharm Tech Holdings Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Cash-to-Debt

Get a 7-Day Free Trial

0.07

0.06

0.07

No Debt

Sinopharm Tech Holdings Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															0.15	N/A	No Debt	N/A	0.85

Competitive Comparison of Sinopharm Tech Holdings's Cash-to-Debt

For the Software - Application subindustry, Sinopharm Tech Holdings's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sinopharm Tech Holdings's Cash-to-Debt Distribution in the Software Industry

For the Software industry and Technology sector, Sinopharm Tech Holdings's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Sinopharm Tech Holdings's Cash-to-Debt falls into.

Sinopharm Tech Holdings Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Sinopharm Tech Holdings's Cash to Debt Ratio for the fiscal year that ended in Jun. 2023 is calculated as:

Sinopharm Tech Holdings had no debt ⁽¹⁾.

Sinopharm Tech Holdings's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	8.505	/	(10	+	0)
	=	0.85

Sinopharm Tech Holdings (HKSE:08156) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Sinopharm Tech Holdings Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Sinopharm Tech Holdings's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Sinopharm Tech Holdings (HKSE:08156) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Technology » Software » Sinopharm Tech Holdings Ltd (HKSE:08156) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

Ruttonjee Centre, 11 Duddell Street, Unit 1802, 18/F, Ruttonjee House, Hong Kong Central, Hong Kong, HKG

Website

https://www.sinopharmtech.com.hk

Sinopharm Tech Holdings Ltd is an investment holding company. The company's operating segment includes Lottery-related services; Provision of Internet Plus services (solution and supply chain), Manufacturing and distribution of personal protective equipment, and Others services. It generates maximum revenue from the internet plus services (solution and supply chain) segment. The Internet plus Supply chain services segment includes the provision of supply chain management, data analysis and related services, and trading of goods through the internet platform. Geographically, it derives a majority of revenue from Hong Kong.

Executives

Best Frontier Investments Limited
Chan Kin Ho Philip	2201 Interest of corporation controlled by you
Lam Yui Keung	2201 Interest of corporation controlled by you
Sinopharm Traditional Chinese Medicine Overseas Holdings Limited	2101 Beneficial owner
Main Key Investments Limited	2201 Interest of corporation controlled by you
Guo Lei	2201 Interest of corporation controlled by you
Integrated Asset Management (asia) Limited	2101 Beneficial owner
Yam Tak Cheung	2201 Interest of corporation controlled by you
Chan Tung Mei	2202 Interest of your spouse
Cheung Kwai Lan	2201 Interest of corporation controlled by you
Tse Siu Hoi	2101 Beneficial owner
Gam Star China Equity (a Sub-fund Of Gam Star Fund P.l.c.)	2102 Investment manager

Sinopharm Tech Holdings (HKSE:08156) Headlines

No Headlines